Literature DB >> 23721718

Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis.

Simone L Broer1, Madeleine Dólleman, Jeroen van Disseldorp, Kimiko A Broeze, Brent C Opmeer, Patrick M M Bossuyt, Martinus J C Eijkemans, Ben Willem Mol, Frank J M Broekmans.   

Abstract

OBJECTIVE: To evaluate whether ovarian reserve tests (ORTs) add prognostic value to patient characteristics, such as female age, in the prediction of excessive response to ovarian hyperstimulation in patients undergoing IVF, and whether their performance differs across clinical subgroups.
DESIGN: Authors of studies reporting on basal FSH, antimüllerian hormone (AMH), or antral follicle count (AFC) in relation to ovarian response to ovarian hyperstimulation were invited to share original data. Random intercept logistic regression models were used to estimate added value of ORTs on patient characteristics, while accounting for between-study heterogeneity. Receiver operating characteristic regression analyses were performed to study the effect of patient characteristics on ORT accuracy.
SETTING: In vitro fertilization clinics. PATIENT(S): A total of 4,786 women for the main analysis, with a subgroup of 1,023 women with information on all three ORTs. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Excessive response prediction. RESULT(S): We included 57 studies reporting on 32 databases. Female age had an area under the receiver operating characteristic curve of 0.61 for excessive response prediction. Antral follicle count and AMH significantly added prognostic value to this. A model with female age, AFC, and AMH had an area under the receiver operating characteristic curve of 0.85. The combination of AMH and AFC, without age, had similar accuracy. Subgroup analysis indicated that FSH performed significantly worse in predicting excessive response in higher age groups, AFC did significantly better, and AMH performed the same. CONCLUSION(S): We demonstrate that AFC and AMH add value to female age in the prediction of excessive response and that, for AFC and FSH, the discriminatory performance is affected by female age.
Copyright © 2013 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Assisted Reproduction; antimullerian horme; antral folicle count; excessive response; ovarian hyperstimulation syndrome

Mesh:

Year:  2013        PMID: 23721718     DOI: 10.1016/j.fertnstert.2013.04.024

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  33 in total

1.  Ovarian biomarkers predict controlled ovarian stimulation for in vitro fertilisation treatment in Singapore.

Authors:  Ryan Wai Kheong Lee; Lay Wai Khin; Marianne Sybille Hendricks; Heng Hao Tan; Sadhana Nadarajah; Nancy Wen Sim Tee; Seong-Feei Loh; Bee Choo Tai; Jerry Ky Chan
Journal:  Singapore Med J       Date:  2020-09       Impact factor: 1.858

2.  The role of gene polymorphisms and AMH level in prediction of poor ovarian response in Egyptian women undergoing IVF procedure.

Authors:  Tarek M K Motawi; Sherine M Rizk; Nadine W Maurice; Ahmed Mohamed Maged; Ayman N Raslan; Ahmed H Sawaf
Journal:  J Assist Reprod Genet       Date:  2017-08-19       Impact factor: 3.412

Review 3.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

4.  Biological variability in serum anti-Müllerian hormone throughout the menstrual cycle in ovulatory and sporadic anovulatory cycles in eumenorrheic women.

Authors:  K A Kissell; M R Danaher; E F Schisterman; J Wactawski-Wende; K A Ahrens; K Schliep; N J Perkins; L Sjaarda; J Weck; S L Mumford
Journal:  Hum Reprod       Date:  2014-06-12       Impact factor: 6.918

5.  Multi-center clinical evaluation of the Access AMH assay to determine AMH levels in reproductive age women during normal menstrual cycles.

Authors:  Clarisa R Gracia; Sanghyuk S Shin; Maureen Prewitt; Janna S Chamberlin; Lori R Lofaro; Kristin L Jones; Marta Clendenin; Katherine E Manzanera; Dennis L Broyles
Journal:  J Assist Reprod Genet       Date:  2018-03-14       Impact factor: 3.412

6.  Basal serum level of Δ4-androstenedione reflects the ovaries' ability to respond to stimulation in IVF cycles: setting up a new reliable index of both ovarian reserve and response.

Authors:  Emanuele Garzia; Valentina Galiano; Laura Guarnaccia; Giovanni Marfia; Giulia Murru; Ellade Guermandi; Jennifer Riparini; Patrizia Sulpizio; Anna Maria Marconi
Journal:  J Assist Reprod Genet       Date:  2022-06-27       Impact factor: 3.357

Review 7.  Artificial Intelligence in the Assessment of Female Reproductive Function Using Ultrasound: A Review.

Authors:  Zhiyi Chen; Ziyao Wang; Meng Du; Zhenyu Liu
Journal:  J Ultrasound Med       Date:  2021-09-15       Impact factor: 2.754

Review 8.  Challenges in Measuring AMH in the Clinical Setting.

Authors:  Hang Wun Raymond Li; David Mark Robertson; Chris Burns; William Leigh Ledger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-05-24       Impact factor: 5.555

Review 9.  Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI).

Authors:  Sarah F Lensen; Jack Wilkinson; Jori A Leijdekkers; Antonio La Marca; Ben Willem J Mol; Jane Marjoribanks; Helen Torrance; Frank J Broekmans
Journal:  Cochrane Database Syst Rev       Date:  2018-02-01

10.  Cut-Off Levels of Anti-Mullerian Hormone for The Prediction of Ovarian Response, In Vitro Fertilization Outcome and Ovarian Hyperstimulation Syndrome.

Authors:  Ali Salmassi; Liselotte Mettler; Jurgen Hedderich; Walter Jonat; Anupama Deenadayal; Soeren von Otte; Christel Eckmann-Scholz; Andreas Gerd Schmutzler
Journal:  Int J Fertil Steril       Date:  2015-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.